MULTIPLE AGONISTS AND USES THEREOF
The invention relates to the field of medical biology, in particular to a tri-agonist polypeptide compound which has triple agonist activity on a glucagon-like peptide-1 receptor (GLP-1R), a glucose-dependent insulinotropic polypeptide receptor (GIP R) and a glucagon receptor (GCG R) and is shown in a general formula (I) or salt or solvate of the tri-agonist polypeptide compound, and relates to application of the tri-agonist polypeptide compound in treatment of metabolic syndromes..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Europäisches Patentamt - (2023) vom: 14. Nov. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
HUANG LIANG [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-11-14, Last update posted on www.tib.eu: 2024-01-29, Last updated: 2024-02-02 |
---|
Patentnummer: |
CN117062618 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA018609252 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA018609252 | ||
003 | DE-627 | ||
005 | 20240202090605.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231201s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA018609252 | ||
035 | |a (EPA)CN117062618 | ||
035 | |a (EPA)84228431 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a HUANG LIANG |e verfasserin |4 aut | |
245 | 1 | 0 | |a MULTIPLE AGONISTS AND USES THEREOF |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2023-11-14, Last update posted on www.tib.eu: 2024-01-29, Last updated: 2024-02-02 | ||
520 | |a The invention relates to the field of medical biology, in particular to a tri-agonist polypeptide compound which has triple agonist activity on a glucagon-like peptide-1 receptor (GLP-1R), a glucose-dependent insulinotropic polypeptide receptor (GIP R) and a glucagon receptor (GCG R) and is shown in a general formula (I) or salt or solvate of the tri-agonist polypeptide compound, and relates to application of the tri-agonist polypeptide compound in treatment of metabolic syndromes. | ||
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a CAO CHUNLAI |4 aut | |
700 | 0 | |a DENG HUIXING |4 aut | |
700 | 0 | |a ZHOU CUI |4 aut | |
700 | 0 | |a HE XIUYI |4 aut | |
700 | 0 | |a LIU XIAOXIAO |4 aut | |
700 | 0 | |a XIE XIN |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 14. Nov. |
773 | 1 | 8 | |g year:2023 |g day:14 |g month:11 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/84228431/publication/CN117062618A1?q=CN117062618 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2023 |b 14 |c 11 |
951 | |a AR | ||
952 | |j 2023 |b 14 |c 11 |